Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus for atherosclerosis-related vascular dysfunction in rheumatoid arthritis
NL-OMON28147Recruiting
- Sponsor
- Novartis
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of everolimus in rheumatoid arthritis (RA), sponsored by Novartis. Primary endpoints: Endothelial activation, Endothelial dysfunction and 1 more. Started Mar 2010; status: recruiting.
02
Drugs
everolimus
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON28147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28147.